NCT05698524 2025-05-20
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
Clinical Trials
10 trialsNCT03939182 2025-04-25
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03592472 2025-04-13
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Xynomic Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT03600441 2025-04-10
FORERUNNER
Xynomic Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT03936153 2025-04-10
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc.
Phase 2 Recruiting
NCT04024696 2025-04-10
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
Xynomic Pharmaceuticals, Inc.
Phase 1/2 Active not recruiting
NCT01543763 2025-03-21
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT03590054 2024-03-22
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
University of California, San Francisco
Phase 1 Completed
NCT01149668 2013-06-19
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Pharmacyclics LLC.
Phase 1 Completed
NCT00562224 2011-09-28
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
Pharmacyclics LLC.
Phase 1 Completed